# Vigil Neuroscience climbs 13% premarket after announcing first participant dosed in Phase 1 clinical trial in healthy volunteers evaluating VG-3927
**FDA Update**

**2023-10-17 13:03**

**https://www.ainvest.com/news/vigil-neuroscience-climbs-13-premarket-after-announcing-first-participant-dosed-in-phase-1-clinical-trial-in-healthy-volunteers-evaluating-vg-3927-2310100006b8c664ce6307ff/**

Vigil Neuroscience climbs 13% premarket after announcing first participant dosed in Phase 1 clinical trial in healthy volunteers evaluating VG-3927